Licensed by Pfizer Catalog No.S1733 Synonyms: NSC-19987
Molecular Weight(MW): 374.47
Methylprednisolone is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
|Description||Methylprednisolone is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation.|
Methylprednisolone (2-10 mg/kg) markedly inhibits TNF production but does not affect serum levels of IL-10, while a high methylprednisolone dose (50 mg/kg) increases LPS-induced IL-10 levels. Methylprednisolone(from 0.01 to 100 mg/mL) also increases the biosynthesis of IL-10 by LPS-activated mouse peritoneal macrophages. 
|In vivo||Methylprednisolone decreases RGC survival in rats with electrophysiologically diagnosed optic neuritis. Methylprednisolone decreases RGC survival by a nongenomic, calcium-dependent mechanism. Methylprednisolone-induced enhancement of RGC degeneration depends on calcium influx through voltage-gated calcium channels.  Methylprednisolone treatment leads to a significant decrease in the number of ED1-positive cells in both rostral and caudal stumps. Methylprednisolone treatment results in a significant reduction in tissue loss in both cord stumps at 2, 4 and 8 week post-injury. Methylprednisolone leads to a long-term reduction of ED1-positive cells and spinal tissue loss, reduced dieback of vestibulospinal fibres, and a transient sprouting of vestibulospinal fibres near the lesion at 1 and 2 weeks post-lesion.  Methylprednisolone at a dose of 30 mg/kg which has been shown to be effective in improving functional outcomes in rat SCI models, suppresses TNF-α expression and NF-kB activation. Methylprednisolone inhibition of NF-kB function is likely mediated by the induction of IkB, which traps NF-kB in inactive cytoplasmic complexes. |
|In vitro||DMSO||75 mg/mL (200.28 mM)|
|Ethanol||2 mg/mL (5.34 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03876444||Not yet recruiting||Drug: Intravenous Methylprednisolone|Drug: Oral Pednisolone||Infantile Spasm||Suvasini Sharma|Lady Hardinge Medical College||April 1 2019||Phase 2|Phase 3|
|NCT03568136||Recruiting||Drug: Secukinumab 300 mg|Drug: Placebo||Dermatitis Atopic|Eczema Atopic|Neurodermatitis Atopic||GWT-TUD GmbH|Novartis Pharmaceuticals||September 18 2018||Phase 2|
|NCT03113695||Recruiting||Drug: Obinutuzumab|Drug: lenalidomide|Drug: HDMP||Richter''s Syndrome|CLL||University of California San Diego||December 20 2017||Phase 1|
|NCT03680495||Recruiting||Drug: Methylprednisolone||COPD|Emphysema or COPD|COPD Exacerbation|COPD Exacerbation Acute|Respiratory Failure|Ventilatory Failure||University of Colorado Denver|National Jewish Health||July 21 2017||--|
|NCT03183284||Unknown status||--||Immune Thrombocytopenia||Assiut University||June 30 2017||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.